FindTrial
Sign In

Oral MRT-2359

DRUG2 trials

Sponsors

Monte Rosa Therapeutics, Inc

Conditions

Castration-Resistant Prostate CancerCastration-Resistant Prostate Cancer (CRPC)DLBCLHR-positive, HER2-negative Breast CancerHigh Grade Neuroendocrine CancerL-MYC and N-MYC Amplified Solid TumorsNSCLCNSCLC With High or Low L-MYC or N-MYC Expression

Phase 1

Study of Oral MRT-2359 in Selected Cancer Patients
Active, not recruitingNCT05546268
Monte Rosa Therapeutics, IncDLBCL, High Grade Neuroendocrine Cancer, HR-positive, HER2-negative Breast Cancer +5
Start: 2022-10-12End: 2027-11-01Target: 174Updated: 2026-03-03

Phase 2

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
RecruitingNCT07745361
Monte Rosa Therapeutics, IncCastration-Resistant Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Prostate Cancer +1
Start: 2026-08-01End: 2028-04-01Target: 25Updated: 2026-08-24

Related Papers

Abstract 3294: The GSPT1 molecular glue degrader MRT-2359 is active against prostate cancer
Cancer Research2024-03-225 citations
Abstract ND10: Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers
Cancer Research2023-05-294 citations
Abstract 3449: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction
Cancer Research2023-04-0414 citations
Abstract 1673: Discovery of potent, selective, and orally bioavailable GSPT1 degraders and their pre-clinical anti-tumor activity in acute myeloid leukemia and solid tumors
Cancer Research2023-04-042 citations